New data published in Brain showing that #leriglitazone halts disease progression in adult patients with progressive #cALD, a fatal neurodegenerative disorder characterized by growing, demyelinating brain lesions.
Minoryx Therapeutics
Biotecnología
Mataró, Barcelona 6491 seguidores
Developing drugs for orphan CNS diseases
Sobre nosotros
Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million
- Sitio web
-
http://www.minoryx.com
Enlace externo para Minoryx Therapeutics
- Sector
- Biotecnología
- Tamaño de la empresa
- De 11 a 50 empleados
- Sede
- Mataró, Barcelona
- Tipo
- De financiación privada
- Fundación
- 2011
- Especialidades
- Rare diseases, Neurometabolic diseases, X-linked Adrenoleukodystrophy, Friedreich's Ataxia y Orphan CNS
Ubicaciones
-
Principal
Cómo llegar
Av. Ernest Lluch 32, TCM2
Mataró, Barcelona 08302, ES
-
Cómo llegar
Rue Auguste Piccard 48
Gosselies, Charleroi 6041, BE
Empleados en Minoryx Therapeutics
Actualizaciones
-
Today is #RareDiseaseDay 2024, a great opportunity to learn more about cerebral #Adrenoluekodystrophy (cALD), a devastating and fatal rare disease. Watch out this film to hear from Prof. Fanny Mochel, a world renowned expert and Director of the Reference Center for Leukodystrophies - La Pitié-Salpêtrière Hospital (Paris), and Karen Harrison from Alex The Leukodystrophy Charity (Alex TLC) who shares powerful insights into the patient experience. Click on the link to watch the film and please spread the word, every share counts in raising awareness for cALD and other rare diseases! https://lnkd.in/dVYzmPft Minoryx Therapeutics Neuraxpharm #ALD #cALD
Rare Disease Day 2024 - Neuraxpharm & Minoryx
https://www.youtube.com/
-
Neuraxpharm and Minoryx Therapeutics announced today that the companies are seeking a re-examination of #leriglitazone for conditional approval for patients with cerebral adrenoleukodystrophy (cALD), following the negative CHMP opinion. cALD is characterized by demyelinating brain lesions which can become rapidly progressive, leading to acute neurological decline and death in three to four years. #Neuraxpharm and #Minoryx believe that leriglitazone could be a lifesaving treatment for these patients in a disease without pharmacological treatment options available. Find out more in the press release here: https://lnkd.in/ddHw2CMf #CNS #cALD #pharmaceuticals #pharma
-
-
First patients enrolled at CALYX! At #Minoryx we are very pleased to announce that we initiated randomization in our FDA approved Phase 3 study evaluating the efficacy of #leriglitazone in adult patients with cerebral #adrenoleukodystrophy (cALD) https://lnkd.in/dX2FB5TS
Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX
minoryx.com
Páginas similares
Buscar empleos
Financiación
Minoryx Therapeutics
10 rondas en total
Ver más información en Crunchbase
Última ronda
Serie C
Enlace externo a Crunchbase para la última ronda de financiación
54.744.055,00 US$